Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) (MALAT1)

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly conserved, nuclear-retained long non-coding RNA (lncRNA) that serves as a critical regulator of gene expression and alternative splicing [1, 10]. It is primarily localized within nuclear speckles, where it acts as a molecular scaffold, interacting with various splicing factors and RNA-binding proteins to modulate the processing of pre-mRNAs [7, 10]. MALAT1 is widely recognized as a potent oncogene, with its overexpression strongly linked to enhanced cell proliferation, migration, and metastasis in numerous cancers, including lung, breast, and colorectal malignancies [1, 4, 17]. Beyond its role in oncology, MALAT1 is implicated in the pathogenesis of metabolic disorders such as diabetes and chronic inflammatory conditions like osteoarthritis [8, 12]. Therapeutic strategies targeting MALAT1 include the use of antisense oligonucleotides (ASOs) to induce RNase H-mediated degradation and small molecules designed to destabilize its unique 3' triple helix structure, which is essential for the transcript's stability [6, 11, 13]. While MALAT1-deficient mice are viable and show no gross developmental defects, suggesting that therapeutic inhibition may have a manageable safety profile, challenges persist regarding efficient nuclear delivery and potential off-target effects [6, 16]. MALAT1 expression levels are increasingly utilized as diagnostic and prognostic biomarkers, as they correlate significantly with advanced disease stages and poor patient survival [15, 17, 19].

Other names

NEAT2Nuclear enriched abundant transcript 2HCNPMALAT-1

RNase H-mediated RNA degradation; Destabilization of the 3' triple helix structure; Inhibition of RNA-protein interactions